292 related articles for article (PubMed ID: 11136306)
1. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
[TBL] [Abstract][Full Text] [Related]
2. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
4. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
5. Somatostatin receptor imaging and therapy of pancreatic endocrine tumors.
van Eijck CH; de Jong M; Breeman WA; Slooter GD; Marquet RL; Krenning EP
Ann Oncol; 1999; 10 Suppl 4():177-81. PubMed ID: 10436816
[TBL] [Abstract][Full Text] [Related]
6. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor: scintigraphy and radionuclide therapy.
Krenning EP; Kooij PP; Pauwels S; Breeman WA; Postema PT; De Herder WW; Valkema R; Kwekkeboom DJ
Digestion; 1996; 57 Suppl 1():57-61. PubMed ID: 8813472
[TBL] [Abstract][Full Text] [Related]
8. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
[TBL] [Abstract][Full Text] [Related]
10. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
11. [Somatostatin receptor scintigraphy].
Rasmussen K; Nielsen JT; Rehling M
Ugeskr Laeger; 2005 Dec; 167(49):4647-50. PubMed ID: 16336855
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor imaging: predictive and prognostic considerations.
Anthony LB; Martin W; Delbeke D; Sandler M
Digestion; 1996; 57 Suppl 1():50-3. PubMed ID: 8813470
[TBL] [Abstract][Full Text] [Related]
13. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
Pauwels S; Leners N; Fiasse R; Jamar F
Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
[No Abstract] [Full Text] [Related]
14. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours.
Hashemi SH; Benjegård SA; Ahlman H; Wängberg B; Forssell-Aronsson E; Billig H; Nilsson O
Br J Surg; 2003 May; 90(5):549-54. PubMed ID: 12734860
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.
Janson ET; Kälkner KM; Eriksson B; Westlin JE; Oberg K
Nucl Med Biol; 1999 Nov; 26(8):877-82. PubMed ID: 10708300
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
[TBL] [Abstract][Full Text] [Related]
18. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR
Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767
[TBL] [Abstract][Full Text] [Related]
19. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging.
Kwekkeboom DJ; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):84-91. PubMed ID: 11965603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]